Author Manuscript Published OnlineFirst on December 6, 2012; DOI: 10.1158/1078-0432.CCR-12-2638 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Lactate Dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas Mark L. McCleland1*, Adam S. Adler1*, Laura Deming1*, Ely Cosino2, Leslie Lee2, Elizabeth M. Blackwood2, Margaret Solon1, Janet Tao1, Li Li3, David Shames4, Erica Jackson5, William F. Forrest6, and Ron Firestein1 1Department of Pathology, 2Department of Translational Oncology, 3Department of Bioinformatics & Computational Biology, 4Department of Molecular Diagnostics & Cancer Cell Biology, 5Department of Research Oncology, and 6Department of Biostatistics, Genentech, Inc., South San Francisco, California, USA * These authors contributed equally to this work Corresponding Author: Ron Firestein, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; Phone: 650-225-8441; Fax: 650-467-2625; E-mail:
[email protected] Running title: LDHB is a regulator of KRAS-dependent lung cancer Key words: LDHB, KRAS, lung cancer, glycolysis, metabolism Conflict of interest: All authors are employed by Genentech, Inc. Number of figures: 6 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 6, 2012; DOI: 10.1158/1078-0432.CCR-12-2638 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relevance Specific molecular subsets of cancer have proven to be difficult to target, leaving patients with few therapeutic options. One such example of this is lung adenocarcinomas that exhibit aberration in the KRAS oncogene. KRAS is altered, through activating mutation and copy number gain, in nearly 30% of lung adenocarcinomas.